President’s Message:
Sally Bradberry, MD

Dear Fellow CTTSS members,

I greet you all from a makeshift office in my living room – a situation to which many of us have become accustomed in recent weeks. I sincerely hope that you are keeping safe and well and managing to balance the challenges of professional and personal life at these difficult times.

As incoming President from 1 May 2020, I would like to thank my predecessor, now Immediate Past President, Jenn Burkey, not only for leading us through such a successful year but also for showing me the ropes of SOT operations.

Missing a get together in Anaheim also meant that we were unable to thank our other outgoing officers, John-Michael Sauer exiting Past President, William (Bill) Mattes exiting Treasurer and Tracey Chen standing down after two years’ service as Councilor. Thank you all. Emma Bowers transitions from Postdoc rep to Secretary/Treasurer – great news and testimony to the fact that being on the Exec can’t be all bad!

Your officers for this year are listed opposite and I look forward to working with them all in the coming months.

Continued on page 2
President’s Message: Continued from page 1

As we accept the disappointment that SOT 2020 in Anaheim had to be cancelled, plans for the 2021 meeting in Orlando are well underway. Upcoming deadlines are included in this issue.

I hope you were inspired to submit proposals and wish you well in their acceptance and delivery.

I am most grateful to some of the founding members of our section; Allister Vale, Ken McMartin, and Richard Wang for their article in this issue about the Foundation of CTTSS it is always good to know where you have come from! Their article includes explanation of the inspiration for our logo. This needs modification in the coming months as part of SOT website redevelopment but we will ensure key aspects are retained within our web pages.

Finally, our section is nothing without its members and I would encourage you each to engage at least one colleague who shares your passion and interest in translational and clinical tox to join the section – membership dues are a vital part of our revenue without which we cannot offer sponsorships and prizes to our young researchers ....who are the future of our society and our science.

Please contact me directly at sallybradberry@nhs.net if you would like to comment or question any part of our activity.

Best wishes to you all,

Sally
Meet the Team

We’re excited to welcome our new CTTSS Executive Members for 2020-21!

Vice President-Elect:
Kai Kehe, MD MBA
Bundeswehr Medical Services Headquarter
Division Force Health Protection
Munich Germany

Dr. Kehe is currently head of the Force Health Protection Division at the Bundeswehr Medical Services Headquarter in Koblenz, Germany. He supervises one preventive medicine research institutes and is actively involved in laboratory work in the Bundeswehr Institute of Pharmacology and Toxicology. He is the German representative in several NATO-Groups dealing with medical countermeasures and force health protection. He received his doctorate in medicine from the Technical University Munich in 1991 and was a postdoctoral fellow at the Bundeswehr Institute of Pharmacology and Toxicology from 1996-1997 and 2001-2010 and at the Walther-Straub Institute of Pharmacology and Toxicology, University of Munich, from 1998-2000. Dr. Kehe has a board certification in pharmacology and toxicology. His main focus of research is the pathophysiology of alkylating agents and the development of respective therapeutic approaches. Dr. Kehe is also a lecturer in pharmacology and toxicology as an assistant professor at the Medical School of the Ludwig-Maximilians-University of Munich. 2016 he earned a Master of Business Administration as part of a two-year post-graduate study course for medical doctors from the University of Neu-Ulm, Germany. He is author/co-author of over 100 publications including peer-reviewed articles and book chapters. He has been a member of the SOT since 2016.

Councilor:
Deidre Dalmas, BS, MS, PhD
GSK Fellow
Fellow Royal Society of Biology
GlaxoSmithKline, Collegeville, PA

Deidre is the Scientific Director of the US Investigative Safety Group within In Vitro / In Vivo Translation at GlaxoSmithKline in Collegeville, PA where she designs and executes bespoke ex vivo and in vitro non-clinical safety studies to help characterize anticipated safety risks for development compounds, defines clinical relevance, and identifies translational marker opportunities across all phases of discovery and development. She received her PhD from the University of the Sciences in Philadelphia in Toxicology (2012), a MS degree from Thomas Jefferson University (2006) and BS degree from Philadelphia College of Pharmacy and Science (1996) both in Pharmacology and Toxicology. In addition, she is also a Translational Safety Team Project Representative supporting all phases of development with emphasis on oncology and epigenetics. Deidre is the Co-Chair of the Drug Induced Vascular Injury (DIVI) Working Group of Predictive Safety Testing Consortium (PSTC). She is a Councilor for the mid-Atlantic Society of Toxicology (MASOT) she and maintains the MASOT website and is on the Program and Awards Committees. She was a graduate student SOT member and volunteered for many years supporting the CE courses at the annual SOT meeting. She serves on the HESI eSTAR Committee of the HESI/ILSI Consortium and is the Chair of the DruSafe Emerging Clinical/Nonclinical Translational Biomarkers Working Group of the IQ Consortium. She is author/co-author of multiple peer-reviewed articles and ad hoc reviewer for various peer-reviewed journals including Toxicological Sciences. Most interestingly, she has been working in on a scientific project in collaboration with the Center for Advancement of Science in Space (CASSIS) and NASA and has an experiment that will be making its way to the International Space Station (ISS) in Sept 2020. In her ‘free’ time, she works as an interior designer at Potterbarn, volunteers at a cat rescue helping to find forever homes for stray or abandoned cats, and loves spending time with her dogs Skye and Maizee.

Continued on page 4
Postdoctoral Representative:
Milan Prajapati, B. Pharm, M.S., Ph.D.
Brown University, Providence, RI 02906
Twitter: @metalbiology
After completing a pharmacy program with distinction (an approximate equivalent of the Latin honor summa cum laude), Milan decided to pursue higher studies in the United States where better research opportunities are available. He joined the graduate program at St. John’s University, Queens, NY, and received his doctorate in 2016. Passionate about research, he is currently a post-doctoral fellow in Dr. Tom Bartnikas’ lab at Alpert Medical School, Brown University, Providence, RI. Milan’s research career has revolved around working with different metals. During his doctoral studies, Milan investigated molecular mechanisms of toxicity due to inhalation exposure of tungsten (W) nanoparticles. While his graduate work focused on environmental/occupational exposure of metals, his post-doctoral research with Dr. Bartnikas is focused on in vivo and in vitro models of inherited/acquired metal toxicity (Fe and Mn). His research on manganese was recognized with a postdoctoral research award by Molecular and Systems Biology Specialty Section (2019), Clinical and Translational Toxicology Specialty Section (2020), and special interest group ASIO (2020). Through his graduate and postdoctoral training, he has developed a strong interest in metal biology and narrowed his focus on studying the molecular mechanisms of toxicity using models of inherited metal excess. Milan has varied leadership experience from his early days in school as prefect (US equivalent to student council) to his current role in the Brown University Postdoc Council. Milan is an active member of SOT since 2013 and has served on the planning committees of SOT’s Mentoring Breakfast, MASOT regional chapter (postdoctoral representative). He has also served on number of education and outreach initiatives such as Dean’s hour: careers in toxicology (Panelist), NY State Science and Education Fair (Judge), and Skype a Scientist. During his career, he has independently taught courses focused on pharmacology and toxicology and has presented his research findings in various settings. Being an aviation enthusiast, Dr. Prajapati enjoys plane spotting and aviation photography in his free time.

The Foundation of the CTTSS in 2011

Circumstances

The SOT Council were keen to encourage the development of clinical and translational toxicology within the Society. This initiative had been stimulated by Michael Ottlinger, then President of the Occupational and Public Health Specialty Section, and it was strongly supported by Jon Cook (President), William Slikker Jr (Vice-President and Chair of the Scientific Program Committee) and Ronald Hines. The Disease Prevention Task Force, which promoted inter-disciplinary activities between SOT members and scientists interested in disease-oriented research and practice, also supported the creation of the CTTSS, as did the Scientific Liaison Coalition.

How we got to here

We were encouraged to assemble a core of enthusiastic, hardworking SOT members. With the input of SOT Council members, we produced draft bylaws and a three-year plan. We defined the purpose and objectives of the new Specialty Section and 50 SOT members supportive of the new Specialty Section were recruited.

The Council approved the establishment of the CTTSS in late 2011 and the CTTSS was run by Interim Officers from its inception until 2013. The Interim Officers were: Allister Vale (President); Kenneth
McMartin (Vice President) John Benitez (Secretary-Treasurer), Richard Wang and Ray Singer (Councilors).

Over 100 members were recruited by the time of the inaugural Specialty Section Reception and Business Meeting which was held on Wednesday 14 March 2012 at 6 pm in the Walnut Room in the Marriott Marquis Hotel, San Francisco. Kenneth McMartin gave a presentation on Translating mechanistic studies into clinical applications.

The 2012 Annual Meeting also featured a Clinical and Translational Toxicology and Disease Prevention session to highlight SOT’s newest Specialty Section. The Translational Impact Award was made to John Benitez.

Balloted elections supervised by the SOT took place before the 2013 SOT Meeting when the Interim Officers (President, Vice President and Secretary-Treasurer) were confirmed and Horst Thiermann was elected as Vice President-Elect, and Richard Wang and Charles Lindamood III were elected as Councilors. Richard Wang was responsible for a successful membership drive which increased the membership substantially to more than 150 members.

Since then...

The CTTSS has served as a forum for SOT members, including students and postdoctoral trainees, with an interest in the impact of pharmaceuticals, chemicals, plants, fungi, toxic terrestrial and marine animals on human health. State-of-the-art knowledge and new approaches that optimize the treatment of these types of exposures have been discussed at CTTSS meetings and in the many symposia and workshops sponsored by the Specialty Section at SOT Annual meetings, particularly those coordinated by members of the CTTSS. The mechanisms of toxicity, toxicokinetics and toxicodynamics of the agent, and the pharmacology and adverse effects of the proposed treatment, has been emphasized.

The CTTSS logo

With the assistance of SOT, the Specialty Section developed a logo and we have been invited to explain its meaning. The logo was designed to show an interaction between basic mechanistic research in toxicology being directly translated into clinical applications.

The pathology background of the logo shows crystals of calcium oxalate monohydrate being associated with severe necrotic damage in the renal proximal tubule of ethylene-glycol treated rats. Basic studies have shown that such crystal accumulation is mechanistically responsible for the acute kidney injury seen in ethylene glycol poisoning in humans. Furthermore, basic studies showed that inhibition of ethylene glycol metabolism could prevent crystal formation; these studies were translated into a successful new therapy for treatment of ethylene glycol poisoning in humans – which is the drug fomepizole, whose structure is seen in the logo. The stethoscope then represents the clinical adaptation of this translated product.

Kenneth McMartin
Allister Vale
Richard Wang
Calling all Clinicians!...

Recruiting clinicians to the CTTSS

Interested in the impact of pharmaceuticals, chemicals, plant and fungi toxins and terrestrial and marine animal venoms on human health? Join the Clinical and Translational Toxicology Specialty Section!

The CTTSS is committed to improving the management of human poisoning by using a translational approach that links molecular mechanisms to rational therapy.

You can join CTTSS or pay membership at any time during the year through the SOT membership renewal.

If you know of colleagues that would benefit from membership in our specialty section, please let them know about us! We are the specialty section for translational science, so spread the word!

**To email the Clinical and Translational Toxicology Specialty Section Leadership, please send an email to SOHQ@toxicology.org.**

Travel Awards

The CTTSS is pleased to announce the opportunity for travel awards, which are intended to help defray some expenses for travel of a graduate student and/or postdoctoral fellow to present their research at the 2021 SOT annual meeting in Orlando. The awardees will receive a monetary prize of $500 and a recognition certificate. Please visit the CTTSS Awards webpage for further application information.